Product information and disease descriptionProduct descriptionProduct information
Effect of Palazestrant on quality measures
6 evidence topics · 6 sources
MIPS Quality ID 453: systemic cancer-directed therapy in the last 14 days of life
MIPS Quality ID 457: hospice admission for less than 3 days before death
MIPS Quality ID 143: pain intensity quantified
MIPS Quality ID 144: plan of care for pain
Enhancing Oncology Model: episodes with hormonal therapy only and quality strategy
Product-specific effect on quality measures
No evidence found.